Asst Prof Raymond Ng Chee Hui

Assistant Professor Ng graduated from Otago Medical School in New Zealand in 1994 and subsequently attained his specialist oncology fellowship from the Royal Australasian College of Physicians in 2004. Following this he spent a year as a Clinical Research Fellow at Royal Melbourne Hospital in Australia and subsequently an additional two years as a Clinical Fellow at Princess Margaret Hospital in Toronto, Canada. His work in Canada focused primarily on clinical care as well as a special interest on health outcomes research in breast and lung cancer. 

He returned to Singapore in 2007 as an Associate Consultant at the National Cancer Centre Singapore and is now currently a Senior Consultant within the breast oncology team. In this intervening period he also completed a Master in Public Health from NUS in 2010. He is also passionate about medical education and spends part of his time every week lecturing and mentoring medical students at the University.

• MPH, National University of Singapore
• FRACP (Medical Oncology) Royal Australasian College of Physicians 
• Dip Obs - University of Otago, New Zealand 
• MB, ChB - University of Otago, New Zealand
  

• Singapore Society of Oncology 
• American Society of Clinical Oncology 
• Royal Australasian College of Physicians
  

• Singapore Health Quality Service Award- Gold category, 2010
  
• EXSA Silver Service Award, 2009
  
• Novartis Oncology Young Canadian Investigator Award recipient, 2006
  

• ​Health outcomes Research
  
• Supportive Care
  

• Wong KM, Ding K, Li S, Bradbury P, Tsao MS, Der SD, Shepherd FA, Chung C, Ng R, Seymour L, Leighl NB. A Cost-Effectiveness Analysis of Using the JBR.10-Based 15-Gene Expression Signature to Guide Adjuvant Chemotherapy in Early Stage Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2017 Jan;18(1):e41-e47. 
• Chan A, Gan YX, Oh SK, Ng T, Shwe M, Chan R, Ng R, Goh B, Tan YP, Fan G. A culturally adapted survivorship programme for Asian early stage breast cancer patients in Singapore: A randomized, controlled trial. Psychooncology. 2016 Dec 26. [Epub ahead of print]. 
• Sutiman N, Lim JS, Muerdter TE, Singh O, Cheung YB, Ng RC, Yap YS, Wong NS, Ang PC, Dent R, Schroth W. Pharmacogenetics of UGT1A4, UGT2B7 and UGT2B15 and their influence on tamoxifen disposition in Asian breast cancer patients. Clinical pharmacokinetics. 2016 Oct 1;55(10):1239-50. 
• Loh KY, Ng T, Lee CP, Ng R, Chan A. Medication use by early-stage breast cancer survivors: a 1-year longitudinal study. Supportive Care in Cancer. 2016 Apr 1;24(4):1639-47. 
• Ng T, Teo SM, Yeo HL, Shwe M, Gan YX, Cheung YT, Foo KM, Cham MT, Lee JA, Tan YP, Fan G, Yong WS, Preetha M, Loh WJ, Koo SL, Jain A, Lee GE, Wong M, Dent R, Yap YS, Ng R, Khor CC, Ho HK, Chan A. Brain-derived neurotrophic factor genetic polymorphism (rs6265) is protective against chemotherapy-associated cognitive impairment in patients with early-stage breast cancer. Neuro-oncology. 2016 Feb 1;18(2):244-51. 
• Lim JS, Sutiman N, Muerdter TE, Singh O, Cheung YB, Ng RC, Yap YS, Wong NS, Siang PA, Dent R, Schroth W. Association of CYP2C19* 2 and Associated Haplotypes with Lower Norendoxifen Levels in Tamoxifen‐treated Asian Breast Cancer Patients. British Journal of Clinical Pharmacology. 2016 Jan 1. 
• Chan A, Gan YX, Oh SK, Ng T, Shwe M, Chan R, Ng R, Goh B, Tan YP, Fan G. A Culturally Adapted Survivorship Program for Asian Early‐Stage Breast Cancer Patients in Singapore: A Randomized, Controlled Trial. Psycho‐Oncology. 2016 Jan 1. 
• Luo N, Cheung YB, Ng R, Lee CF. Mapping and direct valuation: do they give equivalent EQ-5D-5L index scores?. Health and quality of life outcomes. 2015 Oct 5;13(1):1. 
• Cheung YT, Ng T, Shwe M, Ho HK, Foo KM, Cham MT, Lee JA, Fan G, Tan YP, Yong WS, Madhukumar P, Loo SK, Ang SF, Wong M, Chay WY, Ooi WS, Dent RA, Yap YS, Ng R, Chan A. Association of proinflammatory cytokines and chemotherapy-associated cognitive impairment in breast cancer patients: a multi-centered, prospective, cohort study. Annals of Oncology. 2015 Jul 1;26(7):1446-51. 
• Ng R. Too Much Medicine: Time to Stop Indiscriminate Cancer Screening. Annals of the Academy of Medicine, Singapore. 2015 Jun;44(6):194-6.